Studies from Friedrich-Alexander-University Erlangen-Nurnberg (FAU) Have Provided New Information about Cancer (A Concept of Dual-responsive Prodrugs Based On Oligomerization-controlled Reactivity of Ester Groups: an Improvement of Cancer Cells...).

Předmět:	CANCER cells PRODRUGS ESTERS BLOOD cells TECHNOLOGICAL innovations
Zdroj:	Drug Week; 3/15/2024, p1366-1366, 1p
Abstrakt:	Researchers from Friedrich-Alexander-University Erlangen-Nurnberg (FAU) in Germany have developed a new prodrug concept to address the dose-limiting side effect of neutropenia in chemotherapeutic anticancer agents. The prodrug is designed to be activated in cancer cells and primed neutrophils, while remaining inactive in normal cells and neutrophils lacking mitochondria. The researchers demonstrated the effectiveness of the prodrug in vitro and in vivo, showing antitumor activity without toxicity to normal cells and neutrophils. This research provides a potential improvement in cancer treatment by increasing selectivity and reducing side effects. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu